Company: BLNE
Filing Date: 2025-05-15
Form Type: 8-K
Source: 0001641172-25-010657
Chunk: 1

Company: Beeline Holdings, Inc.
Filing Date: 2025-05-15
Form: 8-K
Item: Item 3.02
Chunk 1
---
Item
3.02 Unregistered Sales of Equity Securities.

To
the extent applicable, the disclosure in Item 1.01 is incorporated by reference.

Item
5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements
of Certain Officers

On
May 14, 2025, the Board of Directors appointed Francis Knuettel II to serve on the Board of Directors, effective immediately.

Mr.
Knuettel is a newly-appointed director of the Company. Francis Knuettel II has spent most of his career as a CXO in early-stage public
companies - specializing in dynamic technology and life sciences companies - with a strong track record in growing organizations.
Mr. Knuettel has been Chief Executive Officer of Channel Therapeutics Corporation [NYSE American: CHRO] since July 2023 and Channel’s
Chief Financial Officer since June 2022. He has also been a director since August 2024. Prior to that, from December 2020 to March 2022,
he served as Chief Executive Officer and director of Unrivaled Brands.

There
are no arrangements or understandings between Mr. Knuettel and any other person pursuant to which he was appointed as a director. Mr.
Knuettel has no family relationships with any director or executive officer of the Company, and there are no transactions in which he
has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item
9.01 Financial Statements and Exhibits